Walter Hermans

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction

Burkert Pieske, Rolf Wachter, Sanjiv J. Shah et al. · JAMA · 2021 · 161 citations · Full text

Medicine, Cardiology, Pharmacology +14

Quantitative angiographic assessment of elastic recoil after percutaneous transluminal coronary angioplasty

Benno J. Rensing, Walter Hermans, Kevin J. Beatt et al. · The American Journal of Cardiology · 1990 · 158 citations · Full text

Medicine, Cardiology, Surgery +16

Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group.

Benno J. Rensing, Walter Hermans, J. Cornelis de Vos et al. · Circulation · 1993 · 149 citations · Full text

Medicine, Cardiology, Pharmacotherapy +12

Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial

Patrick W. Serruys, Wolfgang Rutsch, Nicolas Danchin et al. · Data Archiving and Networked Services (DANS) · 1992 · 146 citations · Full text

Medicine, Cardiology, Pharmacotherapy +16